Wolters Kluwer Provides MDS Solution Medi-Span to The Christie NHS Foundation Trust

Key Takeaways

• Wolters Kluwer's Medi‑Span deployed at Europe's largest single‑site cancer centre
• Integration embeds allergy and medication alerts directly into patient records
• First NHS implementation of Medi‑Span, paired with Better Meds ePMA
• Clinicians gain real‑time decision support across all inpatient wards
• Implementation praised for seamless go‑live and collaborative teamwork

Pulse Analysis

The NHS’s push toward digital health has accelerated the adoption of clinical decision‑support systems that can mitigate medication errors, a persistent challenge in high‑volume specialties like oncology. By choosing The Christie—an institution that treats more than 60,000 patients annually—as its inaugural UK partner, Wolters Kluwer demonstrates confidence in Medi‑Span’s scalability and its ability to integrate with existing electronic prescribing infrastructures. This move aligns with broader NHS objectives to harmonize patient data across platforms, ensuring that clinicians have instant access to critical safety information at the point of care.

Medi‑Span’s core strength lies in its extensive drug database and sophisticated clinical APIs, which allow seamless embedding into the Better Meds ePMA solution. The integration supplies personalized alerts for allergies, drug‑drug interactions, and dosage considerations, tailored to each patient’s clinical context. For oncology teams, where polypharmacy is common, such real‑time insights can prevent adverse events, shorten hospital stays, and support compliance with national safety standards. Early feedback from The Christie’s specialist pharmacists highlights a noticeable reduction in manual chart checks and faster prescription turnaround times.

The successful rollout at a high‑profile cancer centre serves as a proof point for other NHS trusts contemplating similar upgrades. As more hospitals adopt interoperable decision‑support tools, Wolters Kluwer stands to expand its footprint across the UK’s public health system, leveraging the credibility earned at The Christie. In the longer term, the partnership could spur innovations such as predictive analytics for chemotherapy regimens, further cementing the role of data‑driven technology in improving patient outcomes across the NHS.